Compare GEO & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEO | MESO |
|---|---|---|
| Founded | 1984 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 1994 | N/A |
| Metric | GEO | MESO |
|---|---|---|
| Price | $15.43 | $16.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $41.00 | $24.00 |
| AVG Volume (30 Days) | ★ 1.7M | 217.9K |
| Earning Date | 02-12-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 515.49 | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $2,531,574,000.00 | $17,198,000.00 |
| Revenue This Year | $7.93 | $576.59 |
| Revenue Next Year | $15.02 | $41.15 |
| P/E Ratio | $9.29 | ★ N/A |
| Revenue Growth | 4.43 | ★ 191.39 |
| 52 Week Low | $14.27 | $9.61 |
| 52 Week High | $32.09 | $21.50 |
| Indicator | GEO | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | 36.80 |
| Support Level | $15.42 | $17.00 |
| Resistance Level | $16.57 | $17.61 |
| Average True Range (ATR) | 0.71 | 0.60 |
| MACD | -0.24 | -0.23 |
| Stochastic Oscillator | 3.85 | 2.40 |
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.